Equity Profile

WST

West Pharmaceutical Services, Inc.

Health CareLife Sciences Tools & Services$25.4B

Jul23Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

West Pharmaceutical Services, Inc. (WST) operates in the health care sector, specifically focusing on life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for future growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

WST Q2-2026 Earnings Preview

Context

Company Snapshot

West Pharmaceutical Services, Inc. (WST) operates in the health care sector, specifically focusing on life sciences tools and services. The company plays a crucial role in providing innovative solutions for drug delivery and packaging, which are essential for the pharmaceutical and biotechnology industries.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+13.50%

Avg Stock Reaction

+0.61%

Last Quarter Recap

In Q1 2026, West Pharmaceutical Services reported an EPS of $2.13, significantly beating estimates by 27%. The stock reacted positively, gaining 12.86% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are generally optimistic about West Pharmaceutical's upcoming earnings, given its strong track record of beating EPS estimates in recent quarters. However, there is uncertainty regarding revenue figures as no estimates are available.

Bull Case

If West Pharmaceutical continues its trend of strong earnings surprises, it could see significant stock appreciation, especially if revenue growth is also robust.

Bear Case

Conversely, if the company fails to meet expectations or if revenue growth is disappointing, it could lead to a sharp decline in stock price, particularly given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to past performance?

Given the company's history of beating EPS estimates, this figure will be crucial in determining market reaction.

What insights can management provide on revenue growth for the upcoming quarter?

Revenue growth is essential for assessing the company's overall health and future prospects, especially in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating West Pharmaceutical's ability to sustain its earnings growth, particularly given its recent strong performance.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a trend that may continue.

Options pricing indicates a higher expected move than historical averages, suggesting that traders anticipate significant news.

The lack of revenue estimates may lead to underappreciation of the company's growth potential.

Key Risk

If the EPS comes in below $2.00, it could challenge the current optimistic sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around whether West Pharmaceutical can maintain its strong earnings momentum amid market challenges.

Bull Confirmed If

An EPS of $2.20 or higher would confirm the bull case and suggest continued strong performance.

Bear Confirmed If

An EPS below $1.90 would confirm the bear case, indicating potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±17.16%

Historical Avg

±14.9%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±17.2% while WST has averaged ±14.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

44.2%

Calls (10K)P/C Ratio: 0.93Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If West Pharmaceutical beats expectations, history suggests a potential stock increase of around 2.75%, confirming the bullish outlook.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may see muted movement as investors reassess future growth.

Miss

A miss could lead to a decline of approximately 14.40%, reflecting investor disappointment and concerns over the company's trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in drug delivery systems.
2Management's outlook on market demand for their services in the next quarter.
3Insights into cost management and operational efficiency improvements.
4Comments on competitive pressures and how they plan to address them.
5Any guidance on future revenue growth expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Domino's Pizza, Inc.

Company Snapshot

West Pharmaceutical Services, Inc. (WST) operates in the health care sector, specifically focusing on life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely watch.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market share and increase sales, which is vital for future growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

WST Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+13.50%

Avg Stock Reaction

+0.61%

Last Quarter Recap

In Q1 2026, West Pharmaceutical Services reported an EPS of $2.13, significantly beating estimates by 27%. The stock reacted positively, gaining 12.86% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If West Pharmaceutical continues its trend of strong earnings surprises, it could see significant stock appreciation, especially if revenue growth is also robust.

Bear Case

Conversely, if the company fails to meet expectations or if revenue growth is disappointing, it could lead to a sharp decline in stock price, particularly given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to past performance?

Given the company's history of beating EPS estimates, this figure will be crucial in determining market reaction.

What insights can management provide on revenue growth for the upcoming quarter?

Revenue growth is essential for assessing the company's overall health and future prospects, especially in a competitive market.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating West Pharmaceutical's ability to sustain its earnings growth, particularly given its recent strong performance.

Supporting Evidence

The company has consistently beaten EPS estimates, suggesting a trend that may continue.

Options pricing indicates a higher expected move than historical averages, suggesting that traders anticipate significant news.

The lack of revenue estimates may lead to underappreciation of the company's growth potential.

Key Risk

If the EPS comes in below $2.00, it could challenge the current optimistic sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers around whether West Pharmaceutical can maintain its strong earnings momentum amid market challenges.

Bull Confirmed If

An EPS of $2.20 or higher would confirm the bull case and suggest continued strong performance.

Bear Confirmed If

An EPS below $1.90 would confirm the bear case, indicating potential issues with profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±17.16%

Historical Avg

±14.9%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±17.2% while WST has averaged ±14.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

44.2%

Calls (10K)P/C Ratio: 0.93Puts (300)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If West Pharmaceutical beats expectations, history suggests a potential stock increase of around 2.75%, confirming the bullish outlook.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may see muted movement as investors reassess future growth.

Miss

A miss could lead to a decline of approximately 14.40%, reflecting investor disappointment and concerns over the company's trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in drug delivery systems.
2Management's outlook on market demand for their services in the next quarter.
3Insights into cost management and operational efficiency improvements.
4Comments on competitive pressures and how they plan to address them.
5Any guidance on future revenue growth expectations.